JP2019514908A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514908A5
JP2019514908A5 JP2018556275A JP2018556275A JP2019514908A5 JP 2019514908 A5 JP2019514908 A5 JP 2019514908A5 JP 2018556275 A JP2018556275 A JP 2018556275A JP 2018556275 A JP2018556275 A JP 2018556275A JP 2019514908 A5 JP2019514908 A5 JP 2019514908A5
Authority
JP
Japan
Prior art keywords
hbd
medicament according
motomeko
defensins
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018556275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514908A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2017/050132 external-priority patent/WO2017186250A1/en
Publication of JP2019514908A publication Critical patent/JP2019514908A/ja
Publication of JP2019514908A5 publication Critical patent/JP2019514908A5/ja
Ceased legal-status Critical Current

Links

JP2018556275A 2016-04-29 2017-04-28 肝臓、胆管および膵臓の障害の治療 Ceased JP2019514908A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201670276 2016-04-29
DKPA201670276 2016-04-29
DKPA201670484 2016-07-01
DKPA201670484 2016-07-01
PCT/DK2017/050132 WO2017186250A1 (en) 2016-04-29 2017-04-28 Treatment of liver, biliary tract and pancreatic disorders

Publications (2)

Publication Number Publication Date
JP2019514908A JP2019514908A (ja) 2019-06-06
JP2019514908A5 true JP2019514908A5 (https=) 2020-06-11

Family

ID=58992579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556275A Ceased JP2019514908A (ja) 2016-04-29 2017-04-28 肝臓、胆管および膵臓の障害の治療

Country Status (13)

Country Link
US (1) US12076368B2 (https=)
EP (1) EP3448409B1 (https=)
JP (1) JP2019514908A (https=)
KR (1) KR102465341B1 (https=)
CN (1) CN109414474B (https=)
AU (1) AU2017258242B2 (https=)
BR (1) BR112018071972A2 (https=)
CA (1) CA3022497A1 (https=)
ES (1) ES3057685T3 (https=)
PL (1) PL3448409T3 (https=)
RU (1) RU2740913C2 (https=)
SG (1) SG11201809086YA (https=)
WO (1) WO2017186250A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
JP7479381B2 (ja) * 2019-01-07 2024-05-08 アエスクルス バイオ エーピーエス 治療または予防に使用するためのディフェンシン断片
CN110279851A (zh) * 2019-07-05 2019-09-27 浙江大学 Defa4细胞因子在制备治疗肝功能衰竭药剂中的应用
CN114058694A (zh) * 2021-11-29 2022-02-18 上海市普陀区中心医院 Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用
KR102735773B1 (ko) * 2022-11-10 2024-11-27 을지대학교 산학협력단 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CA2487895A1 (en) 2002-05-31 2003-12-11 Ciphergen Biosystems, Inc. Defensins: use as antiviral agents
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
US20100104529A1 (en) 2006-05-01 2010-04-29 England Robert L TNF-alpha VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-alpha
JP2009541287A (ja) * 2006-06-20 2009-11-26 リポペプチド・アクチエボラーグ 抗癌剤としてのカテリシジン抗菌タンパク質（ｈＣＡＰ１８）の使用
WO2008115390A2 (en) * 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
SG172709A1 (en) * 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
AP2011005537A0 (en) 2008-07-18 2011-02-28 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins.
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
US20110311601A1 (en) 2010-06-22 2011-12-22 Michael Kleine Antimicrobial medical devices
DE102010040153A1 (de) 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
WO2012177929A2 (en) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
WO2013006692A2 (en) * 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
JP2015533483A (ja) * 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
CN104971343B (zh) * 2015-07-13 2018-02-02 韩源平 防御素在制备治疗代谢综合征药物方面的应用
CN105504063B (zh) * 2015-10-19 2019-10-01 中国医学科学院医药生物技术研究所 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用
BR112018015170A2 (pt) 2016-01-26 2018-12-18 Defensin Therapeutics Aps métodos para tratamento de doenças, para promoção de crescimento magro, para tratamento ou normalização de uma microbiota disbiótica no intestino, para aumentar riqueza gênica da microbiota intestinal, para aumentar número de filos da microbiota intestinal, para aumentar produção de ácidos graxos de cadeia curta da microbiota intestinal/metaboloma, para aumentar número de bactérias, para diminuir número de bactérias, defensina a, defensina ss, ou um fragmento bioativo das mesmas, e, defensina a e/ou defensina ss e/ou um glp-1/análogo de glp-1.
WO2017185549A1 (zh) * 2016-07-30 2017-11-02 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法2
CN114075585A (zh) * 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种β-烟酰胺单核苷酸的制备方法
CN112795606B (zh) * 2021-04-14 2021-07-27 深圳瑞德林生物技术有限公司 一种β-烟酰胺单核苷酸的酶催化合成方法
CN114107160B (zh) * 2021-12-27 2025-04-25 浙江英沃迪生物科技有限公司 一种烟酰胺核糖激酶基因工程菌及其应用

Similar Documents

Publication Publication Date Title
AU2015335828B2 (en) Co-agonists of the glucagon and GLP-1 receptors
AU2016232218B2 (en) Amylin analogues
JP2019514908A5 (https=)
KR102505628B1 (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
TWI523659B (zh) 肽結合物
JP2014504597A (ja) アシル化グルカゴン類似体とインスリン類似体の組合せ物
EP3046573B1 (en) Amylin analogues
CA2965560A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
US20200392197A1 (en) Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
JP2019534248A (ja) アミリン類似体
RU2018141326A (ru) Лечение нарушений со стороны печени, желчных путей и поджелудочной железы
Jaswal et al. Tirzepatide: a first-in-class twincretin for the management of type 2 diabetes
KR20220119475A (ko) 글루카곤 및 glp-1 수용체의 스테이플화된 트리아졸 공-효능제
WO2021133642A1 (en) Stapled lactam co-agonists of the glucagon and glp-1 receptors
HK1184466A (en) Peptide conjugates of glp-1 receptor agonists and gastrin and their use